BRD4 and gastrointestinal stromal tumor: With BRD4 mRNA being preferentially upregulated in aggressive GIST, overexpressed BRD4 confers growth‐promoting and promigratory oncometabolic phenotypes that are associated with adverse clinicopathologic factors and unfavourable RTK genotypes and independently portends decreased DFS.